Literature DB >> 11213356

Human chorionic gonadotropin beta-core fragment is directly produced by cancer cells.

T Okamoto1, R Niu, K Matsuo, M Furuhashi, M Ohsawa, S Mizutani, H Suzuki.   

Abstract

The present study was undertaken to investigate whether hCG beta-core fragment (hCGbeta cf) was directly produced by cancer cells. Fifteen cell lines, including four choriocarcinoma and five ovarian cancer cell lines, were tested, and immunoreactivity of hCGbeta cf was present in the culture media of five of the cell lines. It was also present in the culture media of Chinese hamster ovary (CHO) cells transfected with hCGbeta gene. In addition to hCGbeta cf, gel chromatography and Western blot analysis of the culture media showed the presence of an hCGbeta cf immunoreactive material with a molecular weight of approximately 40 kDa. In an in vivo study, hCGbeta cf immunoreactivity was detected in the sera of the mice transplanted with NaUCC-3 choriocarcinoma cells, although the ratios of hCGbeta cf/hCG and hCGbeta cf/free hCGbeta were lower than those in the culture medium. Incubation experiments of purified hCGbeta cf in the serum showed no substantial decrease in its values, ruling out the possibility that formation of a macromolecule with serum components may mask hCGbeta cf immunoreactivity in the serum. Taken together, these results indicate that hCGbeta cf immunoreactive materials are directly produced by cancer cells and hCGbeta cf is not a urinary metabolite of hCG or hCGbeta alone. Also, reduced levels of hCGbeta cf in the serum compared with that of intact hCG or free hCGbeta are likely due to its short half-life.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11213356     DOI: 10.1016/s0024-3205(00)00986-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  1 in total

1.  Development of a multimarker assay for early detection of ovarian cancer.

Authors:  Zoya Yurkovetsky; Steven Skates; Aleksey Lomakin; Brian Nolen; Trenton Pulsipher; Francesmary Modugno; Jeffrey Marks; Andrew Godwin; Elieser Gorelik; Ian Jacobs; Usha Menon; Karen Lu; Donna Badgwell; Robert C Bast; Anna E Lokshin
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.